Tyme Technologies (TYME) Reports Q2 Loss of $0.03; Cash and Cash Equivalents of $96.6M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. HUM
9. CSCO
10. KTOS

Go back to Tyme Technologies (TYME) Reports Q2 Loss of $0.03; Cash and Cash Equivalents of $96.6M

Tyme Technologies (TYME) Issues Business Update; Reports Q2 Earnings

November 8, 2021 6:51 AM EST

TYME Technologies, Inc. (Nasdaq: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced financial and operating results for its second fiscal quarter ended September 30, 2021.

Second Fiscal Quarter 2022 Business and Recent Highlights:

Commenced enrollment and dosed first patient in OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study examining SM-88 with methoxsalen, phenytoin, and sirolimus (MPS) in patients with metastatic disease who have received two prior hormonal therapies. The trial is being conducted by Georgetown University (NCT04720664) at five MedStar Health hospitals. (MedStar... More